Figure 2From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer Kaplan-Meier curves for (A) overall survival (OS) and (B) progression free survival (PFS) for patients with EGFR-mRNA > median expression ( n = 65) and EGFR-mRNA < median expression ( n = 65). Median OS: 6.8 vs 10.7 months, p = 0.173; median PFS: 2.9 vs 5.9 months, p = 0.116.Back to article page